Discover more insights into Cardiorenal Outcomes

Keywords frequently search together with Cardiorenal Outcomes

Narrow sentence examples with built-in keyword filters

Cardiorenal Outcomes sentence examples within Adverse Cardiorenal Outcomes



Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension



Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease.


Cardiorenal Outcomes sentence examples within Beneficial Cardiorenal Outcomes



Up front



The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis


Cardiorenal Outcomes sentence examples within Improving Cardiorenal Outcomes



Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication.



Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management



Learn more from Cardiorenal Outcomes


More Cardiorenal Outcomes sentence examples
10.1097/MD.0000000000026431

Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients



319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial


More Cardiorenal Outcomes sentence examples
10.1161/HYPERTENSIONAHA.121.14519

Circadian Rhythm, Clock Genes, and Hypertension: Recent Advances in Hypertension


More Cardiorenal Outcomes sentence examples
10.2174/1389557521666210422114909

Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication.



Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.


More Cardiorenal Outcomes sentence examples
10.1007/s10741-021-10111-y

Letter to the Editor regarding the article “SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis”



Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management



FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D


More Cardiorenal Outcomes sentence examples
10.1007/s40256-021-00484-8

Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs


More Cardiorenal Outcomes sentence examples
10.1186/s12933-021-01362-y

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence



The Association of Serum Lactate Level with the Occurrence of Contrast-Induced Acute Kidney Injury and Long-Term Prognosis in Patients Undergoing Emergency Percutaneous Coronary Intervention


More Cardiorenal Outcomes sentence examples
10.1096/fasebj.2021.35.S1.02160

Androgens and Diet Regulation of SARS‐CoV‐2 Viral Entry Proteins: Implications for COVID‐19 Cardiorenal Outcomes Severity in Polycystic Ovary Syndrome



Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators



Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19


More Cardiorenal Outcomes sentence examples
10.3390/diagnostics11020290

Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects



Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease.


More Cardiorenal Outcomes sentence examples
10.1186/s12933-021-01366-8

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs



Association between nocturnal blood pressure dipping and chronic kidney disease among patients with controlled office blood pressure.


More Cardiorenal Outcomes sentence examples
10.1161/CIRC.143.SUPPL_1.066

Abstract 066: Association Between Nocturnal Blood Pressure Dipping Magnitude And Chronic Kidney Disease Risk Among Patients With Controlled Office Blood Pressure



Sleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients


More Cardiorenal Outcomes sentence examples
10.1080/14740338.2021.1898585

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis


More Cardiorenal Outcomes sentence examples
10.1186/s12933-021-01258-x

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study



791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV



Sodium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis



Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options



Effects and Safety of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials


More Cardiorenal Outcomes sentence examples
10.1007/s10557-021-07203-0

Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF



GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials



SGLT2 inhibitors for primary prevention of cardiovascular events



248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial


More Cardiorenal Outcomes sentence examples
10.1016/J.CARDFAIL.2019.07.280

A Prediction Model for Identifying Type 2 Diabetics at Highest Risk of Cardiorenal Outcomes



Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials



Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD



Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom


More Cardiorenal Outcomes sentence examples
10.1007/s00125-019-05069-4

Up front



Class effects of SGLT2 inhibitors on cardiorenal outcomes



Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial



The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis


Learn more from Cardiorenal Outcomes


Cardiorenal Outcomes
Encyclopedia